More on AVBP

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

ArriVent BioPharma (NQ:AVBP)
Delayed: 21.00 +1.80 (9.38%)
Prev. Close $19.20  
Open$19.00 
52 Wk High$ 
52 Wk Low$ 
Day High$21.23 
Day Low$18.18 
P/E N/A  
EPS$ 
Volume3,278,458 


Oct 25, 2026 09:00 AM ArriVent reports 44.8% response rate for ADC ARR-217 in CRC patients
Oct 25, 2026 09:00 AM ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Oct 23, 2026 04:00 PM ArriVent to present phase 1 ADC data at ESMO Congress 2026
Oct 23, 2026 04:00 PM ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
Oct 20, 2026 09:07 AM ArriVent BioPharma (AVBP) PT Lowered to $29 at B.Riley
Oct 19, 2026 08:08 AM Form 8-K ArriVent BioPharma, Inc. For: Oct 19
Oct 19, 2026 08:01 AM ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
Oct 16, 2026 06:07 AM ArriVent BioPharma (AVBP) PT Raised to $27 at Jefferies
Oct 13, 2026 04:01 PM Form SCHEDULE 13G ArriVent BioPharma, Inc. Filed by: Vivo Opportunity Fund Holdings, L.P.
Oct 13, 2026 06:03 AM Form 8-K ArriVent BioPharma, Inc. For: Oct 12
View All Articles

Entities mentioned with AVBP

View All Entities